Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Elranatamab and Isatuximab for the Treatment of Relapsed and Refractory Multiple Myeloma

Trial Status: active

This phase II trial tests how well elranatamab and isatuximab work for treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Elranatamab and isatuximab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving elranatamab and isatuximab may kill more cancer cells in patients with relapsed or refractory multiple myeloma.